Compare Stocks: SYN, KVAC, PLRX, and APLM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APLM Apollomics	$21.15 +0.7%	$23.40	$10.01 ▼ $40.01	$61.21M	1.54	7,063 shs	6,232 shs
KVAC Keen Vision Acquisition	$11.51	$11.51	$11.41 ▼ $18.72	$63.37M	-0.04	14,430 shs	N/A
PLRX Pliant Therapeutics	$0.90 -7.5%	$1.09	$0.88 ▼ $1.95	$60.21M	1.27	390,698 shs	582,310 shs
SYN Synthetic Biologics		$0.00	$0.97 ▼ $4.56	$16.16M	1.38	197,338 shs	57,700 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APLM Apollomics	+4.21%	-5.22%	-3.34%	+14.20%	+8.46%
KVAC Keen Vision Acquisition	0.00%	0.00%	0.00%	-4.69%	-0.26%
PLRX Pliant Therapeutics	-7.46%	-11.77%	-15.90%	-21.75%	-42.68%
SYN Synthetic Biologics	0.00%	0.00%	0.00%	0.00%	0.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APLM Apollomics	$21.15 +0.7%	$23.40	$10.01 ▼ $40.01	$61.21M	1.54	7,063 shs	6,232 shs
KVAC Keen Vision Acquisition	$11.51	$11.51	$11.41 ▼ $18.72	$63.37M	-0.04	14,430 shs	N/A
PLRX Pliant Therapeutics	$0.90 -7.5%	$1.09	$0.88 ▼ $1.95	$60.21M	1.27	390,698 shs	582,310 shs
SYN Synthetic Biologics		$0.00	$0.97 ▼ $4.56	$16.16M	1.38	197,338 shs	57,700 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APLM Apollomics	+4.21%	-5.22%	-3.34%	+14.20%	+8.46%
KVAC Keen Vision Acquisition	0.00%	0.00%	0.00%	-4.69%	-0.26%
PLRX Pliant Therapeutics	-7.46%	-11.77%	-15.90%	-21.75%	-42.68%
SYN Synthetic Biologics	0.00%	0.00%	0.00%	0.00%	0.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APLM Apollomics	1.00	Sell	N/A	N/A
KVAC Keen Vision Acquisition	2.00	Hold	N/A	N/A
PLRX Pliant Therapeutics	2.00	Hold	$3.00	233.37% Upside
SYN Synthetic Biologics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest SYN, KVAC, PLRX, and APLM Analyst Ratings

Date	Company	Brokerage	Action	Rating
10/15/2026	PLRX Pliant Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
9/17/2026	APLM Apollomics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
9/1/2026	APLM Apollomics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
8/17/2026	APLM Apollomics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
7/29/2026	KVAC Keen Vision Acquisition	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold (C-) ➝ Hold (C)
7/28/2026	APLM Apollomics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
7/17/2026	PLRX Pliant Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)

(Data available from 10/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APLM Apollomics	$8.50M	7.24	N/A	N/A	($2.89) per share	-7.32
KVAC Keen Vision Acquisition	N/A	N/A	N/A	N/A	N/A	N/A
PLRX Pliant Therapeutics	$1.58M	35.27	N/A	N/A	$2.95 per share	0.31
SYN Synthetic Biologics	N/A	N/A	N/A	N/A	$4.95 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APLM Apollomics	-$10.94M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KVAC Keen Vision Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PLRX Pliant Therapeutics	-$149.34M	-$1.49	N/A	N/A	N/A	N/A	-52.17%	-40.46%	11/5/2026 (Estimated)
SYN Synthetic Biologics	-$14.27M	-$1.21	N/A	N/A	N/A	N/A	-26.14%	-22.74%	N/A

Latest SYN, KVAC, PLRX, and APLM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	PLRX Pliant Therapeutics	-$0.37	N/A	N/A	N/A	N/A	N/A
8/14/2026	Q2 2026	KVAC Keen Vision Acquisition	N/A	$0.08	N/A	$0.08	N/A	N/A
8/11/2026	Q2 2026	PLRX Pliant Therapeutics	-$0.3418	-$0.36	-$0.0182	-$0.36	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
APLM Apollomics	N/A	N/A	N/A	N/A	N/A
KVAC Keen Vision Acquisition	N/A	N/A	N/A	N/A	N/A
PLRX Pliant Therapeutics	N/A	N/A	N/A	N/A	N/A
SYN Synthetic Biologics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APLM Apollomics	N/A	N/A	N/A
KVAC Keen Vision Acquisition	N/A	N/A	N/A
PLRX Pliant Therapeutics	N/A	9.90	9.90
SYN Synthetic Biologics	N/A	4.14	4.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APLM Apollomics	19.13%
KVAC Keen Vision Acquisition	51.72%
PLRX Pliant Therapeutics	97.30%
SYN Synthetic Biologics	74.38%

Insider Ownership

Company	Insider Ownership
APLM Apollomics	N/A
KVAC Keen Vision Acquisition	80.20%
PLRX Pliant Therapeutics	8.74%
SYN Synthetic Biologics	2.15%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APLM Apollomics	15	2.91 million	N/A	Not Optionable
KVAC Keen Vision Acquisition	N/A	5.51 million	1.09 million	Not Optionable
PLRX Pliant Therapeutics	49	61.92 million	56.51 million	Optionable
SYN Synthetic Biologics	16	15.84 million	15.50 million	Not Optionable

SYN, KVAC, PLRX, and APLM Headlines

Recent News About These Companies

SonicStrategy Closes $2.25 Million SYN Token Financing

October 8, 2026 | newsfilecorp.comN

Synthetic Biology Market Size, Share, Growth, Trends, Applications, Competitive Landscape, and Forecast, 2026 to 2034 | 17.6% CAGR Fuels AI-Driven Biomanufacturing Opportunities

September 30, 2026 | finance.yahoo.com

China Cell Culture Microcarrier Consumables Market Poised for Strong Growth Through 2031, Led by Biologics Demand, Synthetic Microcarriers and Biopharmaceutical Applications

September 29, 2026 | finance.yahoo.com

SonicStrategy Acquires Additional SYN Tokens and Announces Grant of Stock Options

September 24, 2026 | newsfilecorp.comN

Tirzepatide Plus Biologics May Improve Outcomes in Psoriatic Arthritis

September 22, 2026 | rheumatologyadvisor.comR

Cell Line Development: A Story of Innovation in Biologics and Cell-Based Therapies

August 26, 2026 | technologynetworks.comT

Protein Design & Engineering Market Global Report 2026: Evaluating AI Platforms, Rational Design, Directed Evolution, and Strategies of Lonza, Thermo Fisher, GenScript, and ...

August 19, 2026 | finance.yahoo.com

Isto Biologics Strengthens its Bone Graft Substitutes Platform with the Acquisition of NovaBone

August 4, 2026 | finance.yahoo.com

Vivex Biologics Launches VIA Linx™, a Novel Self-Assembling Synthetic Peptide Matrix, Expanding its Portfolio of Advanced Wound Care Solutions

July 21, 2026 | markets.businessinsider.com

Computational design drives new generation of synthetic promoters

March 27, 2026 | drugtargetreview.comD

Gene Synthesis Market Comprehensive Industry Analysis, Trends, and Future Outlook

February 25, 2026 | pharmiweb.comP

6 ways biologics is advancing in spine

February 19, 2026 | beckersspine.comB

Stopping Biologics Before Surgery May Raise Flare Risk in RA

January 27, 2026 | rheumatologyadvisor.comR

Study Shows NanoFuse(R) Superiority: Why Bioactive Glass-DBM Composites Outperform DBM and Bioactive Glass Alone

January 26, 2026 | marketwatch.com

MTF Biologics and Kolosis BIO Launch New Solution for Orthopedic and Spinal Surgeries: Summit Matrix™

January 15, 2026 | uk.finance.yahoo.com

MTF Biologics and Kolosis BIO Launch New Solution for Orthopedic and Spinal Surgeries: Summit Matrix(TM)

January 15, 2026 | marketwatch.com

Asimov and AGC Biologics Team Up to Provide a Cost-Effective, Simplified, and Secure Manufacturing Approach for Viral Vector Production

January 13, 2026 | pharmiweb.comP

4 orthobiologics updates

December 18, 2025 | beckersspine.comB

Exposure to Some DMARDs in Fathers-to-Be Tied to Birth Risks

December 2, 2025 | medscape.comM

Relapse in Juvenile Idiopathic Arthritis After Stopping DMARDs: Key Factors Found

December 1, 2025 | medscape.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

SYN, KVAC, PLRX, and APLM Company Descriptions

Apollomics NASDAQ:APLM

$21.15 +0.15 (+0.71%)

Closing price 10/16/2026 03:47 PM Eastern

Extended Trading

$21.15 0.00 (0.00%)

As of 10/16/2026 07:30 PM Eastern

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its also developing uproleselan (APL-106) that is in Phase 3 clinical trial for the treatment of adult patients with relapsed or refractory AML, as well as Phase 2/3 study with uproleselan for the treatment of newly diagnosed older adults with AML; and APL-108, a second-generation E-selective inhibitor, which has completed Phase 1 clinical trials to treat other liquid and solid cancers. The company's pipeline consists of preclinical stage immuno-oncology product candidates, such as APL-501, APL-502, APL-801 and APL-810. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. The company was incorporated in 2015 and is based in Foster City, California.

Keen Vision Acquisition NASDAQ:KVAC

$11.51 0.00 (0.00%)

As of 10/15/2026

Keen Vision Acquisition Corporation does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, and related business combination with one or more businesses or entities. It also intends to focus on businesses in the biotechnology, consumer goods, and agriculture sectors. The company was incorporated in 2021 and is based in Summit, New Jersey.

Pliant Therapeutics NASDAQ:PLRX

$0.90 -0.07 (-7.46%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$0.94 +0.04 (+4.23%)

As of 10/16/2026 07:52 PM Eastern

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Synthetic Biologics NYSEAMERICAN:SYN

Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Synthetic Biologics, Inc. is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SYN, KVAC, PLRX, and APLM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SYN, KVAC, PLRX, and APLM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SYN, KVAC, PLRX, and APLM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SYN, KVAC, PLRX, and APLM Company Descriptions

Apollomics NASDAQ:APLM

Keen Vision Acquisition NASDAQ:KVAC

Pliant Therapeutics NASDAQ:PLRX

Synthetic Biologics NYSEAMERICAN:SYN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SYN, KVAC, PLRX, and APLM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SYN, KVAC, PLRX, and APLM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SYN, KVAC, PLRX, and APLM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SYN, KVAC, PLRX, and APLM Company Descriptions

Apollomics NASDAQ:APLM

Keen Vision Acquisition NASDAQ:KVAC

Pliant Therapeutics NASDAQ:PLRX

Synthetic Biologics NYSEAMERICAN:SYN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools